[Determination of serum pancreatic polypeptide and its clinical significance in patients with end state renal failure].
Serum levels of pancreatic polypeptide (SPP) responding to 75g glucose (oral) challenge were observed in 27 patients with end state renal failure (ESRF) and 27 normal subjects as a control. The results showed that the levels of SPP were significantly higher in ESRF patients than in normal subjects. Dialysis therapy seemed to have no effect on the levels of SPP. The elevated levels of SPP could return to normality after kidney transplantation. There was no positive correlation between the levels of SPP, the blood sugar, and the serum insulin. It is suggested that kidneys are the important sites for the metabolism of PP. The elevated SPP concentration in patients with ESRF may result from their renal failure, and may contribute to some gastrointestinal symptoms which are frequently associated with ESRF.